1. A PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UMBRALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE INTOLERANT TO PRIOR BTK OR PI3K DELTA INHIBITOR THERAPY. (12th June 2019) Authors: Mato, A.R.; Schuster, S.J.; Lamanna, N.; Pagel, J.M.; Flinn, I.W.; Barrientos, J.; Reeves, J.A.; Cheson, B.D.; Barr, P.M.; Kambhampati, S.; Lansigan, F.; Pu, J.J.; Skarbnik, A.; Fonseca, G.; Dorsey, C.; LaRatta, N.M.; Weissbrot, H.; Svoboda, J.; Luning Prak, E.T.; Tsao, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 88 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PHASE I/II STUDY OF UMBRALISIB (TGR‐1202) IN COMBINATION WITH UBLITUXIMAB (TG‐1101) AND PEMBROLIZUMAB IN PATIENTS WITH REL/REF CLL AND RICHTER'S TRANSFORMATION. (12th June 2019) Authors: Mato, A.R.; Svoboda, J.; Luning Prak, E.T.; Schuster, S.J.; Tsao, P.Y.; Dorsey, C.; Sarmasti, L.M.; Becker, P.S.; Brander, D.M.; Nasta, S.; Landsburg, D.J.; King, C.M.; Morrigan, B.; Elwell, J.; Kennard, K.; Roeker, L.; Zelenetz, A.D.; Purdom, M.; Paskalis, D.; Sportelli, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 119 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗